In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
US biopharma Altimmune has entered the conversation about weight loss, joining the likes of Novo Nordisk and Eli Lilly by presenting positive data in the potentially lucrative field. 1 December 2023
Biotechnology
The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for Merck& Co’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC). 1 December 2023
Pharmaceutical
UK pharma major AstraZeneca said today it has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (sodium zirconium cyclosilicate). 1 December 2023
Biotechnology
Immix Biopharma hosted a key opinion leader (KOL) event highlighting the long-term potential for NXC-201, the company’s B-cell maturation antigen (BCMA) targeting CAR-T therapy to address the fragile amyloid light chain amyloidosis (ALA) patient population. 1 December 2023
Pharmaceutical
Industry commentator GlobalData has produced research into growth in the pharma contract manufacturing sector, noting a strong increase in investments. 1 December 2023
Biotechnology
Privately-held Swiss dermatology company Galderma has turned a frown into a smile in sharing the latest news on its drug relabotulinumtoxinA (QM-1114), a novel liquid formulation botulinum toxin A. 30 November 2023
Pharmaceutical
Shares in BioVie closed 61% lower on Wednesday. 30 November 2023
Biotechnology
British biotech Levicept has appointed Eliot Forster as chief executive, with the company’s founder, Simon Westbrook, taking up the role of chief scientific officer. 30 November 2023
Pharmaceutical
Japanese pharma major Astellas today presented 24-week results from the Phase IIIb DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant, at the 15th Congress of the European Society of Gynecology (ESG) in Amsterdam. 30 November 2023
Biotechnology
Shares of US antibody-drug conjugate (ADC) specialist ImmunoGen shot up more that 83% to $29.46 pre-market today, on the news of a definitive agreement to be acquired by pharma major AbbVie. 30 November 2023
Pharmaceutical
Boston, USA-based biopharma Karuna Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) to treat schizophrenia in adults. 30 November 2023
Biosimilars
South Korea’s Samsung Bioepis is the latest to reach an agreement for a biosimilar of Stelara (ustekinumab). 30 November 2023
Biotechnology
Industry analyst GlobalData has highlighted the potential of CAR T-cell therapy advancements in China, noting a relative lack of partnerships with global pharma companies. 30 November 2023
Biotechnology
Top-line results from the single-arm Phase II LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) have been released by AbbVie. 30 November 2023
Biotechnology
Canada-headquartered Phenomic AI yesterday revealed a strategic collaboration and licensing agreement with family-owned German pharma major Boehringer Ingelheim to discover targets important in stroma-rich cancers. 30 November 2023
Pharmaceutical
Several Latin American countries, given their processes of political change, are immersed in deep discussions about transforming their health systems, writes The Pharma Letter's local correspondent. 29 November 2023
Biotechnology
The National Institute for Health and Care Excellence (NICE) has opted against recommending Crysvita (burosumab) to treat adults in England and Wales who have a confirmed diagnosis of X-linked hypophosphataemia (XLH). 29 November 2023
Biotechnology
UK biotech Arecor Therapeutics’ shares edged up more than 2% to 190.00 pence today, after it announced the signing of further collaboration agreement with US pharma major Eli Lilly. 29 November 2023
Pharmaceutical
As political leaders from around the world get ready to meet at the COP 28 climate conference, life science companies are taking steps to encourage sustainability within industry. 29 November 2023
Biotechnology
California, USA-based biotech firm BioMarin Pharmaceutical (Nasdaq: BMRN) has announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for Roctavian (valoctocogene roxaparvovec-rvox) for people with severe hemophilia A. 29 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze